SPY412.27-3.80 -0.91%
DIA338.12-3.18 -0.93%
IXIC13,818.41-131.81 -0.94%

BRIEF-Lilly Presents Patient-Reported Outcomes From The Positive Phase 3 Monarche Trial For Verzenio At St. Gallen Virtual Congress 2021

· 03/17/2021 06:54
BRIEF-Lilly Presents Patient-Reported Outcomes From The Positive Phase 3 Monarche Trial For Verzenio At St. Gallen Virtual Congress 2021

- Eli Lilly and Co LLY.N:

  • LILLY PRESENTS PATIENT-REPORTED OUTCOMES FROM THE POSITIVE PHASE 3 MONARCHE TRIAL FOR VERZENIO® AT ST. GALLEN VIRTUAL CONGRESS 2021

  • ELI LILLY AND CO - PRO DATA FURTHER SUPPORT MONARCHE RESULTS TO DATE FOR VERZENIO FOR TREATMENT OF HR+, HER2- HIGH RISK EARLY BREAST CANCER

  • ELI LILLY AND CO - MONARCHE TRIAL IS ONGOING AND PATIENTS WILL CONTINUE TO BE FOLLOWED TO ASSESS SAFETY, PROS AND OTHER ENDPOINTS

  • ELI LILLY-ADDITION OF VERZENIO TO ET DID NOT RESULT IN CLINICALLY MEANINGFUL DIFFERENCE IN PATIENTS REPORTING BEING BOTHERED BY TREATMENT SIDE EFFECTS

Source text for Eikon: ID:nPnbY6QQCa

Further company coverage: LLY.N


((reuters.briefs@thomsonreuters.com;))